Cited by 193Lipoproteins and Cardiovascular HealthDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.

Statins for the prevention of dementia

McGuinness, Bernadette, Craig, David, Bullock, Roger, Passmore, Peter·2009·Cochrane Database of Systematic Reviews

DOI 10.1002/14651858.cd003160.pub2

Open this paper in CoChat — free account

Abstract

Background This is an update of a Cochrane review first published in 2001. At that stage there was insufficient evidence to recommend statins for the prevention of Alzheimer's disease (AD). The scope of this review has been expanded to include all forms of dementia. Objectives To assess the effects of statins in the prevention of dementia. Search strategy The Specialized Register of the Cochrane Dementia and Cognitive Improvement Group, The Cochrane Library, MEDLINE, EMBASE, PsycINFO, CINAHL and LILACS were searched on 10 October 2007 using the terms statin*, lovastatin*, pravastatin*, simvastatin*, fluvastatin*, atorvastatin* and rosuvastatin*. The CDCIG Register contains records from many healthcare databases, SIGLE, LILACS as well as many trials databases and is updated regularly. Selection criteria Double-blind randomized placebo-controlled trials of statins in people at risk of AD and dementia. Data collection and analysis Two independent reviewers extracted and assessed data independently and agreement was reached after discussion. Adverse effects were noted. Main results Two trials were identified with 26,340 participants; HPS 2002 and PROSPER 2002. Age range was 40-82 years across the two studies, PROSPER 2002 included 5804 patients aged 70-82 years and HPS included 20,536 patients with 5806 at least 70 years old at study entry. Mean total cholesterol 5.9 mmol/l, LDL cholesterol 3.4 mmol/l at study entry with mean reduction in LDL cholesterol of 1.0 mmol/l in simvasta…

Integrity signals

Registry

Crossref · 10.1002/14651858.cd003160.pub2

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67394-1 · Cited by 6,848
Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.
Brookmeyer, R., Gray, S. G., & Kawas, C. H. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,802
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
CNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711
Brain Infarction and the Clinical Expression of Alzheimer Disease<subtitle>The Nun Study</subtitle>
Snowdon, D. A. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340047031 · Cited by 1,590
Decreased Prevalence of Alzheimer Disease Associated With 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors
Wolozin, B. L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,408
Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., Strooper, B. D., Beyreuther, K. T., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,177
Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study
Breteler, M. M. B., Swieten, J. C. V., Bots, M. L., Grobbee, D. E., Claus, J. J., Hout, J. H. W. V. D., van Harskamp, F., Tanghe, H. L. J., de Jong, P. T. V. M., van Gijn, J., et al. (1994) · Neurology · doi:10.1212/wnl.44.7.1246 · Cited by 1,006
Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts
Ehehalt, R., Keller, P., Haass, C., Thiele, C., & Simons, K. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200207113 · Cited by 932
Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo
Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081620098 · Cited by 860
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: The Hisayama Study
Yoshitake, T., Kiyohara, Y., Kato, I., Ohmura, T., Iwamoto, H., Nakayama, K., Ohmori, S., Nomiyama, K., Kawano, H., Ueda, K., et al. (1995) · Neurology · doi:10.1212/wnl.45.6.1161 · Cited by 829
High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules
COCKERILL, G. W., Rye, K., Gamble, J. R., Vadas, M. A., & Barter, P. J. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.11.1987 · Cited by 788
Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model
Refolo, L. M., Pappolla, M. A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G. S., Sambamurti, K., & Duff, K. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0304 · Cited by 783
Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation
Lütjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Sidén, A., Diczfalusy, U., & Björkhem, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9799 · Cited by 682
Serum Total Cholesterol, Apolipoprotein E {FC12}e4 Allele, and Alzheimer’s Disease
Notkola, I.-L., Sulkava, R. O., Pekkanen, J., Erkinjuntti, T., Ehnholm, C., Kivinen, P., Tuomilehto, J., & Nissinen, A. (1998) · Neuroepidemiology · doi:10.1159/000026149 · Cited by 679
Apolipoprotein E ε4 Allele, Elevated Midlife Total Cholesterol Level, and High Midlife Systolic Blood Pressure Are Independent Risk Factors for Late-Life Alzheimer Disease
Kivipelto, M., Helkala, E., Laakso, M. P., Hänninen, T., Hallikainen, M., Alhainen, K., Iivonen, S., Mannermaa, A., Tuomilehto, J., Nissinen, A. M., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-3-200208060-00006 · Cited by 642
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation
Björkhem, I., Lütjohann, D., Diczfalusy, U., Ståhle, L., Ahlborg, G., & Wahren, J. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32188-x · Cited by 538
Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study
Ott, A., Slooter, A., Hofman, A., van Harskamp, F., Witteman, J., Van Broeckhoven, C., van Duijn, C., & Breteler, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07541-7 · Cited by 535
Use of Lipid-Lowering Agents, Indication Bias, and the Risk of Dementia in Community-Dwelling Elderly People
Rockwood, K. J., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H. R., Verreault, R., Wolfson, C. M., & McDowell, I. (2002) · Archives of Neurology · doi:10.1001/archneur.59.2.223 · Cited by 520
Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles
Thiele, C., Hannah, M. J., Fahrenholz, F., & Huttner, W. B. (2000) · Nature Cell Biology · doi:10.1038/71366 · Cited by 498
HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species
Waßmann, S., Laufs, U., Bäumer, A. T., Müller, K., Ahlbory, K., Linz, W., Itter, G., Rösen, R., Böhm, M., & Nickenig, G. (2001) · Hypertension · doi:10.1161/01.hyp.37.6.1450 · Cited by 453
The design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 448
Serum Lipoprotein Levels, Statin Use, and Cognitive Function in Older Women
Yaffe, K. S., Barrett-Connor, E. L., Lin, F., & Grady, D. G. (2002) · Archives of Neurology · doi:10.1001/archneur.59.3.378 · Cited by 445
Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol
Sparks, D. L., Scheff, S. W., Hunsaker, J. C., Liu, H., Landers, T., & Gross, D. R. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1044 · Cited by 443
Association of γ-Secretase with Lipid Rafts in Post-Golgi and Endosome Membranes
Vetrivel, K. S., Cheng, H., Lin, W., Sakurai, T., Li, T., Nukina, N., Wong, P. C., Xu, H., & Thinakaran, G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407986200 · Cited by 413
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Reitz, C., Tang, M.-X., Luchsinger, J., & Mayeux, R. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.705 · Cited by 397
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease
Wolozin, B. L., Wang, S. W., Li, N.-C., Lee, A. F., Lee, T. A., & Kazis, L. E. (2007) · BMC Medicine · doi:10.1186/1741-7015-5-20 · Cited by 391
Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients
Lütjohann, D., Papassotiropoulos, A., Björkhem, I., Locatelli, S., Bagli, M., Oehring, R. D., Schlegel, U. S., Jessen, F., Rao, M. L., von Bergmann, K., et al. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32052-6 · Cited by 378
Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease
Jarvik, G. P., Wijsman, E. M., Kukull, W. A., Schellenberg, G. D., Yu, C., & Larson, E. B. (1995) · Neurology · doi:10.1212/wnl.45.6.1092 · Cited by 372
Statin‐Associated Memory Loss: Analysis of 60 Case Reports and Review of the Literature
Wagstaff, L. R., Mitton, M. W., McLendon-Arvik, B., & Doraiswamy, P. M. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.7.871.32720 · Cited by 366
Cholesterol Modulates α-Secretase Cleavage of Amyloid Precursor Protein
Bodovitz, S., & Klein, W. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4436 · Cited by 359
Isoprenoids as mediators of the biological effects of statins
Liao, J. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216421 · Cited by 352
Neuropathological assessment of the lesions of significance in vascular dementia
Esiri, M. M., Wilcock, G. K., & Morris, J. H. (1997) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.6.749 · Cited by 347
The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function
Posner, H. B., Tang, M. X., Luchsinger, J. A., Lantigua, R., Stern, Y., & Mayeux, R. P. (2002) · Neurology · doi:10.1212/wnl.58.8.1175 · Cited by 330
Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease? The Cache County Study
Zandi, P. P. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.2.217 · Cited by 317
Effects of lovastatin on cognitive function and psychological well-being
Muldoon, M. F., Barger, S. D., Ryan, C. M., Flory, J. D., Lehoczky, J. P., Matthews, K. A., & Manuck, S. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00353-3 · Cited by 290
Statin Use and the Risk of Incident Dementia
Rea, T. D., Breitner, J. C. S., Psaty, B. M., Fitzpatrick, A. L., López, O. L., Newman, A. B., Hazzard, W. R., Zandi, P. P., Burke, G. L., Lyketsos, C. G., et al. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1047 · Cited by 277
Cholesterol and Alzheimer’s disease
Simons, M., Keller, P., DICHGANS, J., & Schulz, J. B. (2001) · Neurology · doi:10.1212/wnl.57.6.1089 · Cited by 257
Statin therapy and risk of dementia in the elderly
Li, G., Higdon, R., Kukull, W. A., Peskind, E. R., Moore, K. V. V., Tsuang, D. W., van Belle, G., McCormick, W. C., Bowen, J. D., Teri, L. L., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000142963.90204.58 · Cited by 250
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults
Muldoon, M. F., Ryan, C. M., Sereika, S. M., Flory, J. D., & Manuck, S. B. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.07.041 · Cited by 250
Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol
Lange, Y., Ye, J., Rigney, M., & Steck, T. L. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32101-5 · Cited by 245
Lipid-lowering drugs
Pahan, K. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5406-7 · Cited by 241
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease
Li, G., Larson, E. B., Sonnen, J. A., Shofer, J. B., Petrie, E. C., Schantz, A. M., Peskind, E. R., Raskind, M. A., Breitner, J. C. S., & Montine, T. J. (2007) · Neurology · doi:10.1212/01.wnl.0000277657.95487.1c · Cited by 240
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia
Dufouil, C., Richard, F., Fiévet, N., Dartigues, J., Ritchie, K. A., Tzourio, C., Amouyel, P., & Alpérovitch, A. (2005) · Neurology · doi:10.1212/01.wnl.0000160114.42643.31 · Cited by 238
Amyloidogenic processing of β-amyloid precursor protein in intracellular compartments
Vetrivel, K. S., & Thinakaran, G. (2006) · Neurology · doi:10.1212/01.wnl.0000192107.17175.39 · Cited by 227
Low-Density Lipoprotein Cholesterol and the Risk of Dementia With Stroke
Moroney, J. T. (1999) · JAMA · doi:10.1001/jama.282.3.254 · Cited by 222
Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study.
Sharrett, A. R., Patsch, W., Sorlie, P. D., HEISS, G. M., Bond, M. G., & DAVIS, C. E. (1994) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.14.7.1098 · Cited by 214
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Arvanitakis, Z., Schneider, J. A., Wilson, R. S., Bienias, J. L., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000288181.00826.63 · Cited by 203
Association between Statin Use and Alzheimer’s Disease
ZAMRINI, E. Y., McGwin, G., & Roseman, J. M. (2004) · Neuroepidemiology · doi:10.1159/000073981 · Cited by 201
Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanović, N., Gandy, S., Lannfelt, L., Terenius, L. Y., & Nordstedt, C. (1995) · Neuron · doi:10.1016/0896-6273(95)90079-9 · Cited by 197
Association between high‐density lipoprotein and cognitive impairment in the oldest old
van Exel, E. R., de Craen, A. J. M., Gussekloo, J., Houx, P. J., Wiel, A. B. D., Macfarlane, P. W., Blauw, G. J., & Westendorp, R. G. J. (2002) · Annals of Neurology · doi:10.1002/ana.10220 · Cited by 189
The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment
Hajjar, I. M., Schumpert, J., Hirth, V., Wieland, D. M., & Eleazer, G. P. (2002) · The Journals of Gerontology Series A · doi:10.1093/gerona/57.7.m414 · Cited by 188
Status of Risk Factors for Vascular Dementia
Skoog, I. G. (1998) · Neuroepidemiology · doi:10.1159/000026147 · Cited by 177
Serum Cholesterol and Cognitive Performance in the Framingham Heart Study
Elias, P. K., Elias, M. F., D’Agostino, R. B., SULLIVAN, L. M., & Wolf, P. A. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000151745.67285.c2 · Cited by 168
Is Alzheimer's disease an apolipoprotein E amyloidosis?
Wisniewski, T., Lalowski, M., Golabek, A., Frangione, B., & Vogel, T. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90701-7 · Cited by 155
Cognitive Impairment Associated with Atorvastatin and Simvastatin
King, D. S., Wilburn, A. J., Wofford, M. R., Harrell, T. K., Lindley, B. J., & Jones, D. W. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.15.1663.31953 · Cited by 152
Removal of cholesterol from extrahepatic sources by oxidative mechanisms
Björkhem, I., Diczfalusy, U., & Lütjohann, D. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199904000-00010 · Cited by 131
Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins
Reid, P., Urano, Y., Kodama, T., & Hamakubo, T. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00054.x · Cited by 131
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial
Sparks, D. L., Connor, D. J., Sabbagh, M. N., Petersen, R. B., Lopez, J., & Browne, P. J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00690.x · Cited by 130
Association Between Apolipoprotein E 4 and Cognitive Decline in Elderly Adults
Packard, C. J., Westendorp, R. G. J., Stott, D. J., CASLAKE, M. J., Murray, H. M., Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., et al. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01415.x · Cited by 127
Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Co-localization of cholesterol, apolipoprotein E and fibrillar Aβ in amyloid plaques
Burns, M. P., Noble, W. J., Olm, V., Gaynor, K., Casey, E., LaFrancois, J. J., Wang, L., & Duff, K. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00647-2 · Cited by 117
Cholesterol-dependent Generation of a Seeding Amyloid β-Protein in Cell Culture
Mizuno, T., Nakata, M., Naiki, H., Michikawa, M., Wang, R., Haass, C., & Yanagisawa, K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.21.15110 · Cited by 117
Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia
Paragh, G., Balla, P., Katona, E., Seres, I., Égerházi, A., & Degrell, I. (2002) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060200013 · Cited by 114
Effect of Pharmacologic Lipid Lowering on Health‐Related Quality of Life in Older Persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study
Santanello, N. C., Barber, B., Applegate, W. B., Elam, J. T., Curtis, C., Hunninghake, D. B., Gordon, D. J., & For the CRISP Collaborative Study Group (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb00971.x · Cited by 101
Reduced Risk of Incident AD with Elective Statin Use in a Clinical Trial Cohort
Sparks, D., Kryscio, R., Sabbagh, M., Connor, D., Sparks, L., & Liebsack, C. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132316 · Cited by 92
Statins for the prevention of Alzheimer's disease and dementia
Scott, H. D., & Laake, K. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160 · Cited by 91
High density lipoproteins reduce organ injury and organ dysfunction in a rat model of hemorrhagic shock
COCKERILL, G. W., McDonald, M. C., Mota‐Filipe, H., Cuzzocrea, S., Miller, N. E., & Thiemermann, C. (2001) · The FASEB Journal · doi:10.1096/fj.01-0075com · Cited by 90
Use of Lipid‐Lowering Drugs in Older Adults With and Without Dementia: A Community‐Based Epidemiological Study
Rodríguez, E., Dodge, H. H., Birzescu, M., Stoehr, G. P., & Ganguli, M. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50515.x · Cited by 90
Vascular factors in dementia: an overview
DeCarli, C. S. (2004) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2004.09.005 · Cited by 88
Neuropathological Substrates of Dementia and Depression in Vascular Dementia, with a Particular Focus on Cases with Small Infarct Volumes
Ballard, C. G., McKeith, I. G., O'Brien, J. T., Kalaria, R. N., Jaros, E., Ince, P. G., & Perry, R. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017215 · Cited by 87
Serum Cholesterol and Intellectual Performance
Muldoon, M. F., Ryan, C. M., Matthews, K. A., & Manuck, S. B. (1997) · Psychosomatic Medicine · doi:10.1097/00006842-199707000-00008 · Cited by 83
Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients
Harris, J. I., Hibbeln, J. R., Mackey, R. H., & Muldoon, M. F. (2004) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2004.06.001 · Cited by 82
Is There a Connection Between the Concentration of Cholesterol Circulating in Plasma and the Rate of Neuritic Plaque Formation in Alzheimer Disease?
Haley, R. W. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1410 · Cited by 75
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics
Jones, R. W., Kivipelto, M., Feldman, H., Sparks, L. D., Doody, R. S., Waters, D. D., Hey‐Hadavi, J., Breazna, A., Schindler, R. J., Ramos, H., et al. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.02.001 · Cited by 72
HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN DIFFERENTIAL DIAGNOSIS OF SENILE DEMENTIA
Muckle, T. J., & Roy, J. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92866-1 · Cited by 67
The Role of Cholesterol and Statins in Alzheimer's Disease
Miller, L. J., & Chacko, R. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d104 · Cited by 62
Plasma antioxidant activity and vascular dementia
Ryglewicz, D., RODO, M., Kunicki, P. K., Bednarska‐Makaruk, M., Graban, A., Łojkowska, W., & Wehr, H. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00290-3 · Cited by 57
Cholesterol Lowering in the Elderly
LaRosa, J. C. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420050081008 · Cited by 56
Paraoxonase 1 Activity: A New Vascular Marker of Dementia?
DANTOINE, T. F., Debord, J., Merle, L., LACROIX‐RAMIANDRISOA, H., Bernard‐Bourzeix, L., & Charmes, J. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04802.x · Cited by 55
Subchronic Toxicity of Atorvastatin, a Hydroxymethylglutaryl-Coenzyme A Reductase Inhibitor, in Beagle Dogs
Walsh, K. M., Albassam, M., & Clarke, D. E. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400409 · Cited by 54
Effects of simvastatin on the metabolism of polyunsaturated fatty acids and on glycerolipid, cholesterol, and de novo lipid synthesis in THP-1 cells
Risé, P., Colombo, C., & Galli, C. L. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37414-9 · Cited by 50
Enhanced oxidizability of ubiquinol and α‐tocopherol during lovastatin treatment
Palomäki, A., Malminiemi, K., & Metsä‐Ketelä, T. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00609-1 · Cited by 49
Serum cholesterol concentrations are associated with visuomotor speed in men: findings from the third National Health and Nutrition Examination Survey, 1988–1994
Zhang, J., Muldoon, M. F., & McKeown, R. E. (2004) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.2.291 · Cited by 45
Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Berry, P. H., MacDonald, J. S., ALBERTS, A. W., Molon-Noblot, S., Chen, J. S., Lo, C. Y., Greenspan, M. D., Allen, H., Durand-Cavagna, G., & Jensen, R. (1988) · PubMed Central · Cited by 41
Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease
Zuliani, G., Blè, A., Zanca, R., Munari, M. R., Zurlo, A., Vavalle, C., Atti, A. R., & Fellin, R. (2001) · BMC Geriatrics · doi:10.1186/1471-2318-1-5 · Cited by 35
Apolipoprotein E alleles and hyperlipoproteinemia in Japan
Eto, M., Watanabe, K., & Ishii, K. K. (1988) · Clinical Genetics · doi:10.1111/j.1399-0004.1988.tb02871.x · Cited by 23
Monoclonal antibody 14F7, which recognizes a stage-specific immature oligodendrocyte surface molecule, inhibits oligodendrocyte differentiation mediated in co-culture with astrocytes
Yoshimura, K., Sakurai, Y., Nishimura, D., Tsuruo, Y., Nomura, M., Kawato, S., Seiwa, C., Iguchi, T., Itoh, K., & Asou, H. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19981001)54:1 · Cited by 15
[Vascular dementia and systemic changes].
Klich‐Rączka, A., Nęcki, M., Wizner, B., Baron, T., Adamkiewicz-Piejko, A., Gryglewska, B., & Grodzicki, T. K. (2002) · PubMed · Cited by 11
APP Processing Enzymes (Secretases) as Therapeutic Targets: Insights from the Use of Transgenics (Tgs) and Transfected Cells
Marks, N., & Berg, M. J. (2003) · Neurochemical Research · doi:10.1023/a:1023211323853 · Cited by 11
New Possible Role of Statins in Age‐Related Diseases
Ruocco, A., Postiglione, A., Santillo, M., Serù, R., Avvedimento, E. V., Cuda, G., & Paternò, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50631.x · Cited by 11
Statins for the treatment of Alzheimer's disease and dementia
McGuinness, B., Bullock, R. A., Craig, D., Kerr, E., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007514 · Cited by 7
Self-citation
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2

Flagged first, then by citations

1 of the 105 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Kuriyama, 1994, Low levels of serum apolipoprotein A I and A II in senile dementia, Japanese Journal of Psychiatry and Neurology, 48, 589
Refolo, 2001, A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of alzheimer's disease, Neurobiological Disorders, 8, 890

Sorted by citations

Vascular Contributions to Cognitive Impairment and Dementia: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Alzheimer's disease
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336
Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660
A commentary on studies presenting projections of the future prevalence of dementia
Norton, S., Matthews, F. E., & Brayne, C. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-1 · Cited by 634
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation
Andrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 593

See all 193

Authors: McGuinness, B., Craig, D., Bullock, R., & Passmore, P.
Affiliations: Queen's University Belfast (GB)
Victoria Hospital (CA)
ORCID: McGuinness, Bernadette
Craig, David
Passmore, Peter
Venue: Cochrane Database of Systematic Reviews
Publisher: John Wiley & Sons, Ltd
Published: 2009-04-15
Issue: 2
Pages: CD003160-CD003160
ISSN: 1361-6137 (ISSN-L)
DOI: 10.1002/14651858.cd003160.pub2
OpenAlex: W4210956788
Cited by: 193
References: 105
Citations by year: 2025: 3 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 17 · 2015: 18 · 2014: 17 · 2013: 18 · 2012: 22
Type: reference entry
Language: en
Update notices: new_version (2016-01-04)
Open access: closed
Locations: Cochrane Database of Systematic Reviews (publishedVersion)
PubMed (publishedVersion)
Research Portal (Queen's University Belfast) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: statins, dementia prevention, Alzheimer's disease, simvastatin, pravastatin, cognitive function, LDL cholesterol lowering, adverse effects, statin safety, older adults, hypercholesterolemia, dementia incidence, cholesterol-lowering drugs
MeSH terms: Alzheimer Disease, Anticholesteremic Agents, Cognition, Dementia, Humans, Randomized Controlled Trials as Topic, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Statins for the prevention of dementia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks